Clinical and dosimetric factors for symptomatic radiation pneumonitis after stereotactic body radiotherapy for early-stage non-small cell lung cancer

de Koning, 2020, Reduced lung-cancer mortality with volume CT screening in a randomized trial, N Engl J Med, 382, 503, 10.1056/NEJMoa1911793 Chang, 2015, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, Lancet Oncol, 16, 630, 10.1016/S1470-2045(15)70168-3 Tomita, 2022, Role of stereotactic body radiotherapy for early-stage non-small-cell lung cancer in patients borderline for surgery due to impaired pulmonary function, Asia Pac J Clin Oncol, 18, 634, 10.1111/ajco.13731 Sogono, 2021, Safety, efficacy, and patterns of failure after single-fraction stereotactic body radiation therapy (SBRT) for oligometastases, Int J Radiat Oncol Biol Phys, 109, 756, 10.1016/j.ijrobp.2020.10.011 Barriger, 2012, A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy, Int J Radiat Oncol Biol Phys, 82, 457, 10.1016/j.ijrobp.2010.08.056 Baker, 2013, Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung, Int J Radiat Oncol Biol Phys, 85, 190, 10.1016/j.ijrobp.2012.03.041 Allibhai, 2013, The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 87, 1064, 10.1016/j.ijrobp.2013.08.020 Chang, 2014, Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”, Int J Radiat Oncol Biol Phys, 88, 1120, 10.1016/j.ijrobp.2014.01.022 Takeda, 2018, Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy, J Thorac Dis, 10, 247, 10.21037/jtd.2017.12.22 Ricardi, 2009, Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy, Acta Oncol, 48, 571, 10.1080/02841860802520821 Yamashita, 2007, Exceptionally high incidence of symptomatic grade 2–5 radiation pneumonitis after stereotactic radiation therapy for lung tumors, Radiat Oncol, 2, 10.1186/1748-717X-2-21 Baba, 2010, Clinical outcomes of stereotactic body radiotherapy for stage I non-small cell lung cancer using different doses depending on tumor size, Radiat Oncol, 5, 10.1186/1748-717X-5-81 Kita N, Tomita N, Takaoka T, Sudo S, Tsuzuki Y, Okazaki D, et al. Comparison of recurrence patterns between adenocarcinoma and squamous cell carcinoma after stereotactic body radiotherapy for early-stage lung cancer. Cancers (Basel) 2023;15. doi: 10.3390/CANCERS15030887. Tomita, 2021, Surgery versus stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: propensity score-matching analysis including the ratio of ground glass nodules, Clin Transl Oncol, 23, 638, 10.1007/s12094-020-02459-8 Shibamoto, 2012, Radiobiological evaluation of the radiation dose as used inhigh-precision radiotherapy: Effect of prolonged deliverytime and applicability of the linear-quadratic model, J Radiat Res, 53, 1, 10.1269/jrr.11095 Baker, 2016, A critical review of recent developments in radiotherapy for non-small cell lung cancer, Radiat Oncol, 11 Kanda, 2013, Investigation of the freely available easy-to-use software “EZR” for medical statistics, Bone Marrow Transplant, 48, 452, 10.1038/bmt.2012.244 Timmerman, 2006, Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer, J Clin Oncol, 24, 4833, 10.1200/JCO.2006.07.5937 Fakiris, 2009, Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study, Int J Radiat Oncol Biol Phys, 75, 677, 10.1016/j.ijrobp.2008.11.042 Song, 2009, Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus, Lung Cancer, 66, 89, 10.1016/j.lungcan.2008.12.016 Bezjak, 2019, Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial, J Clin Oncol, 37, 1316, 10.1200/JCO.18.00622 Liu, 2021, Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer, Radiother Oncol, 156, 231, 10.1016/j.radonc.2020.10.015 Okubo, 2017, Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours, Br J Radiol, 90, 20160508, 10.1259/bjr.20160508 Ueki, 2015, Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer, J Thorac Oncol, 10, 116, 10.1097/JTO.0000000000000359 Onishi, 2018, Stereotactic body radiation therapy for patients with pulmonary interstitial change: High incidence of fatal radiation pneumonitis in a retrospective multi-institutional study, Cancers (Basel), 10, 257, 10.3390/cancers10080257 Parker, 2019, Impact of tumor size on local control and pneumonitis after stereotactic body radiation therapy for lung tumors, Pract Radiat Oncol, 9, e90, 10.1016/j.prro.2018.09.003 Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, et al. Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012;83. doi: 10.1016/J.IJROBP.2012.01.018. Zhao, 2016, Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: A pooled analysis of 88 studies, Int J Radiat Oncol Biol Phys, 95, 1357, 10.1016/j.ijrobp.2016.03.024 Nakamura, 2008, Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy, Lung, 186, 91, 10.1007/s00408-007-9063-5 Kong, 2021, Organs at risk considerations for thoracic stereotactic body radiation therapy: What is safe for lung parenchyma?, Int J Radiat Oncol Biol Phys, 110, 172, 10.1016/j.ijrobp.2018.11.028